Study indicates Corgenix Medical diagnostic test to be effective

An independent study has indicated that a rapid diagnostic test (RDT) from Corgenix Medical Corp. is effective in determine the presence of the Ebola virus in a patient, the company announced on Tuesday. | Courtesy of Corgenix
An independent study has indicated that a rapid diagnostic test (RDT) from Corgenix Medical Corp. is effective in determine the presence of the Ebola virus in a patient, the company announced on Tuesday.

The study consisted of point-of-care testing at a red-zone in Sierra Leone, a space where suspected Ebola patients are managed and treated. A total of 106 individuals were selected for the study, and the ReEBOV test kit matched the diagnostic results of traditional lab equipment at 100 percent.

The study results were published in Lancet, a British medical journal, and the study was conducted by the Partners in Health Organization.
Over 15,000 cases have been confirmed by laboratory tests over the course of the Ebola outbreak in West Africa.

This assay is the first of its kind that has been approved for use in emergencies by the Food and Drug Administration; it can also be used when authorized Ebola nucleic acid tests are not available.

“In this independent study, the ReEBOV RDT worked exactly as designed," Principal Investigator for the Viral Hemorrhagic Fever Consortium Dr. Robert Garry said. "The best and proper use of the Corgenix Ebola RDT is in villages or neighborhoods, as well as in medical triage units, so that Ebola cases can be appropriately segregated while waiting for secondary testing by polymerase chain reaction (PCR).”